Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Telix securities between February 21, 2025, and August 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action settlements [4].

Group 1 - The core focus of Telix Pharmaceuticals Ltd. is on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [1] - A class action has been filed on behalf of all investors who purchased or acquired Telix securities during the class period from February 21, 2025, to August 28, 2025 [1]

Company Overview - Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biotechnology company focused on developing treatments for prostate and kidney cancer [2] - The company's prostate cancer therapy candidate TLX591 is currently in a phase three study called ProstACT, which aims to enroll approximately 490 patients [2] Recent Developments - On December 8th, Telix Pharmaceuticals announced that it had dosed the first patient in part two of the ProstACT study [2] - In September, the company received Medicare and Medicaid's Transitional Pass-Through payment status for its prostate cancer imaging agent Gozellix, allowing hospitals to receive separate reimbursement for its use [3] Financial Performance - In the third quarter, Telix Pharmaceuticals reported $206 million in revenue, reflecting a 53% annual growth [3] - The company increased its fiscal 2025 revenue guidance to $820 million from $800 million, with revenue from imaging products like Gozellix contributing significantly to sales [3]

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased securities during the specified class period, alleging misleading statements regarding the company's business and operations [1][3]. Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [2]. Allegations - The lawsuit claims that the defendants made false or misleading statements, including: - Materially overstated progress on prostate cancer therapeutic candidates [3]. - Exaggerated quality and performance of the company's supply chain and partners [3]. - Resulting statements about the company's business, operations, and prospects were allegedly false or lacked a reasonable basis [3]. Investor Information - Investors who purchased Telix securities during the class period have until January 9, 2026, to seek appointment as lead plaintiff representative [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by January 9, 2026, to serve as lead plaintiff, representing other class members [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates, leading to significant investor losses [2][4]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements about the progress of its prostate cancer therapeutic candidates [4]. - It is claimed that Telix materially overstated the quality of its supply chain and partners, resulting in misleading statements about its business operations and prospects [4]. - The lawsuit asserts that when the true details about Telix's situation became public, investors suffered damages [4]. Group 2: Impact on Stock Price - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission regarding Telix's disclosures, the price of Telix's American Depositary Shares fell more than 13% over two trading sessions [5]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA, which identified deficiencies in its product TLX250-CDx, causing the stock price to drop more than 21% over two trading sessions [6]. Group 3: Legal Proceedings - Investors who purchased Telix securities between February 21, 2025, and August 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - There is a deadline of January 9, 2026, for investors to seek the role of lead plaintiff in the federal securities class action against Telix [2][7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who bought Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 9, 2026 [3] - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. for alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [2]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [2]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to alleged misstatements regarding the development of its prostate cancer drug TLX591 and deficiencies in its third-party manufacturing processes, leading to significant investor losses [2][3][6]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock price [2][6]. - The SEC is reportedly questioning the accuracy of Telix's development disclosures, while the FDA rejected a Biologics License Application (BLA) due to serious deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][6]. Allegations of Misrepresentation - The complaint claims that Telix and its executives materially overstated the progress of their therapeutic candidates and misrepresented the reliability of their supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, contradicting the company's claims of significant progress and global manufacturing capabilities [3][6]. Investor Impact - The cumulative effect of the regulatory disclosures has led to substantial financial losses for investors who purchased Telix's American Depositary Shares (ADSs) during the class period from February 21, 2025, to August 28, 2025 [6]. - Following the final regulatory news, Telix's ADSs experienced a sharp decline, highlighting the impact of the alleged misstatements on investor confidence [2][6].